Nama Insights

ADARx Pharmaceuticals (ADRX)

Healthcare · Biotechnology · NASDAQ

ADARx Pharmaceuticals (ADRX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.57B and a free-cash-flow yield of 24.3%. Nama's AI scorecard rates it Hold, 5.5 out of 10.
AI scorecard
Hold · 5.5/10
The sections balance. As of Nov 20, 2026.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-44.9%
How far the last close sits under the highest price of the past five years.
Market cap$1.57B
Trailing P/E—
Price / book—
Price / sales236.0
FCF yield24.3%
Dividend yield—
Gross margin0.0%
Operating margin-1735.0%
Net margin0.0%
Revenue growth (YoY)—
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta—
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

ADRX earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate -$0.37). Beat the EPS estimate in 0 of 1 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 12, 2026 -$1.74 -$0.73 -138.4% $2.22M

ADRX analyst price target

Median target $33.50 from 4 analysts, ranging $32.00 – $36.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live ADRX data on Nama Insights →

ADRX FAQ

Is ADRX a buy?
Nama's AI scorecard currently rates ADARx Pharmaceuticals Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ADRX report earnings?
ADARx Pharmaceuticals's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.37.
What is the ADRX price target?
The median analyst price target from 4 analysts is $33.50, with a range of $32.00 – $36.00.
Is ADRX Shariah compliant?
Nama's AAOIFI-style screen reads ADARx Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.